Search Results for "Payment"

The Drug Pricing Lab commissioned Milliman to prepare a report exploring the impact of changes in Medicare Part B program costs on beneficiaries’ premiums and Social Security payments. This report focuses on the 2022 Part B premium for beneficiaries with various income levels to illustrate the payment dynamics and discusses the implications for related programs.

Drug prices in the United States are some of the highest in the world, which has triggered several policy proposals aimed at adopting pricing strategies used by other countries.

CMS delays the effective date of MCIT rule on "breakthrough" designation after concerns raised by physicians, including Peter Bach.

Research Biostatistician, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center

Drug prices in the U.S. are highest among developed countries, effectively setting the upper bound for reference prices elsewhere.

Dr. Peter Bach responds to PhRMA's stance of opposition to H.R. 3 Lower Drug Costs Now Act of 2019.

Dr. Peter Bach, alongside Kathy Sego, Dr. Douglas Holtz-Eakin, and Dr. Mark Miller, testified before U.S. Senate Finance Committee at its first hearing of the session, Drug Pricing in America: A Prescription for Change, Part I.

An overview of the original subscription-based Netflix model proposed and the proposals put forth by Louisiana and Washington.

Our response to the Trump administration’s Request for Information on implementing an international pricing index model for Medicare Part B drugs.

The Drug Pricing Lab takes issue with The New York Times "Fact Check" on the recent Trump Administration proposal to pilot alternative reimbursement for Part B drugs.

As the 340B program expands, it continues to draw national attention.

An alternative payment model is proposed to support a population-level payment paradigm.

Potential strategies for CMS's evaluation of coverage and payment for the various CAR-T therapies are laid out.

Supply chain intermediaries, or “middlemen,” are being blamed for capturing much of the money that is often categorized as drug spending.

A look at Medicare Part B's Competitive Acquisition Program ahead of President Trump's Blueprint to Lower Drug Prices.

A taxonomy of the features that make a payment model truly value-based.

The Centers for Medicare & Medicaid Services (CMS) finalizes OPPS changes for 2018, including ASP -22.5% for drugs obtained through the 340B program.

The Drug Pricing Lab submits a response to CMS-1678-P proposed changes to the Hospital Outpatient Prospective Payment Policy (OPPS).

What happens when a patient uses a copay coupon?

The way Medicare Part D's benefit design shows that rebates actually increase patients' out-of-pocket costs while shifting spending from plan sponsors and manufacturers to Medicare.

A new analysis reviews several analyses of differential costs of care provided in the doctors office and hospital outpatient settings.

Margot Sanger-Katz reports on the negative effects of drug coupons, citing a paper written by Dr. Peter Ubel and Dr. Peter Bach that outlines the issue and prescribes policy solutions.

Members of Congress provided conflicting forecasts on how the agency's proposed pilot program of Part B drug payment might affect aspects of Medicare beneficiary care.

A new analysis sheds light on why proposed changes to the system are being met with opposition and what they could mean for providers and patients.

A controversial effort by the Obama administration to reform how doctors earn money from administering injection drugs would reduce their earnings on the most expensive drugs while making many older generics more lucrative.

Margot Sanger-Katz discusses how doctors are incentivized to prescribe more expensive treatments, and how CMS is devising new payment strategies to combat the practice.

A new plan would seek to change practice of paying doctors more for prescribing higher-priced drugs.